Immunome IMNM Business Segments — Net Income Loss

Similar metrics at other companies

EWTXSingle Reportable — Net Income Loss

-$49.01M-20.1%

VERXSingle Reportable — Net Income Loss

-$2.51M-123%

POWISingle Reportable — Net Income Loss

$3.3M-62.5%

LQD

LQDASingle Reportable — Net Income Loss

$52.86M+238%

ACLSSingle Reportable — Net Income Loss

$9.21M-67.8%

MCRISingle Reportable — Net Income Loss

$27.59M+38.9%

Questions, answered.

What is Immunome's business segments — net income loss?

Immunome (IMNM) reported business segments — net income loss of -$53.84M in Q1 2026.

How has Immunome's business segments — net income loss changed year-over-year?

Immunome's business segments — net income loss decreased by 29.3% year-over-year, from -$41.64M to -$53.84M.

What is the long-term trend for Immunome's business segments — net income loss?

Over 2 years (2023 to 2025), Immunome's business segments — net income loss has grown at a 41.0% compound annual growth rate (CAGR), from -$106.81M to -$212.39M.

What does business segments — net income loss mean?

The bottom-line financial result, representing the total profit or loss after all operating expenses, interest, and other non-operating items are accounted for. This is the ultimate measure of the company's financial performance and its ability to generate value for shareholders. It reflects the net impact of all business decisions, including R&D investments and corporate financing activities.